Zivo Bioscience Announces Board Election and Approvals

An announcement from Zivo Bioscience ( (ZIVO) ) is now available.

At the annual meeting of shareholders held on June 9, 2025, Zivo Bioscience, Inc. announced the election of two Class III directors to its Board of Directors for a three-year term, the ratification of BDO USA, P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2025, and the approval of executive compensation on an advisory basis. With approximately 66.11% of the company’s common stock represented, all proposals were approved by the shareholders, indicating strong support for the company’s governance and financial strategies.

Spark’s Take on ZIVO Stock

According to Spark, TipRanks’ AI Analyst, ZIVO is a Underperform.

Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company’s negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.

To see Spark’s full report on ZIVO stock, click here.

More about Zivo Bioscience

Average Trading Volume: 882

Technical Sentiment Signal: Sell

Current Market Cap: $47.63M

For detailed information about ZIVO stock, go to TipRanks’ Stock Analysis page.